Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.40 |
| ▸ | FAAH | O00519 | 1/20 | 0.40 |
| ▸ | GLP1R | P43220 | 8/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | RECQL | P46063 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | NCF1 | P14598 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15259279 | 1.00 | CES2 (0.46) | CES2MEN1KMT2AEPHX2FAAH | |
| SCHEMBL12807256 | 1.00 | CES2 (0.46) | CES2MEN1KMT2AEPHX2FAAH | |
| SCHEMBL13154532 | 0.97 | CES2 (0.42) | CES2MEN1KMT2AEPHX2FAAH | |
| SCHEMBL16350546 | 0.95 | CES2 (0.50) | CES2MEN1KMT2AEPHX2FAAH | |
| SCHEMBL253658 | 0.95 | CES2 (0.43) | CES2MEN1KMT2AEPHX2FAAH | |
| SCHEMBL26376485 | 0.91 | CES2 (0.44) | CES2MEN1KMT2AFAAHGLP1R | |
| SCHEMBL13034773 | 0.90 | CES2 (0.43) | CES2MEN1KMT2AFAAHGLP1R | |
| SCHEMBL17697227 | 0.90 | CES2 (0.49) | CES2EPHX2FAAHGLP1RTSHR | |
| SCHEMBL72044 | 0.90 | CES2 (0.42) | CES2MEN1KMT2AEPHX2FAAH | |
| SCHEMBL13113388 | 0.90 | CES2 (0.42) | CES2MEN1KMT2AEPHX2FAAH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024073622-A2 | RADIOPHARMACEUTICAL COMPOSITIONS TARGETING EPHRIN TYPE-A RECEPTOR 2 AND USES THEREOF | RAYZEBIO, INC. (US) | 2024-04-04 | — | — | WO | disclosed |
| US-9480753-B2 | FGF21 derivatives with albumin binder A-B-C-D-E- and their use | NOVO NORDISK A/S (DK) | 2016-11-01 | — | — | US | disclosed |
| US-9067977-B2 | Peptides derivatized with A-B-C-D- and their therapeutical use | NOVO NORDISK A/S (DK) | 2015-06-30 | — | — | US | disclosed |
| US-9067977-B2 | Peptides derivatized with A-B-C-D- and their therapeutical use | NOVO NORDISK A/S (DK) | 2015-06-30 | — | — | US | disclosed |
| US-20140011732-A1 | Peptides Derivatized with A-B-C-D- and their Therapeutical Use | NOVO NORDISK A/S (DK) | 2014-01-09 | — | — | US | disclosed |
| US-20140011732-A1 | Peptides Derivatized with A-B-C-D- and their Therapeutical Use | NOVO NORDISK A/S (DK) | 2014-01-09 | — | — | US | disclosed |
| US-8536122-B2 | Acylated GLP-1 compounds | NOVO NORDISK A/S (DK) | 2013-09-17 | — | — | US | disclosed |
| US-20100216715-A1 | FGF21 Derivatives With Albumin Binder A-B-C-D-E- And Their Use | NOVO NORDISK A/S (DK) | 2010-08-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140011732-A1 | Peptides Derivatized with A-B-C-D- and their Therapeutical Use | GLP1R, IAPP, GIPR | CES2 3338/4885MEN1 2167/4885KMT2A 4267/4885 |
| US-20100216715-A1 | FGF21 Derivatives With Albumin Binder A-B-C-D-E- And Their Use | FABP1, FABP4, FGFR1 | CES2 1274/4885MEN1 4363/4885KMT2A 4434/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.